QIAGEN N.V. (QGEN)
Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
Bridgefront Capital LLC Takes Position in Qiagen N.V. $QGEN
Bridgefront Capital LLC bought a new position in shares of Qiagen N.V. (NYSE: QGEN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 13,650 shares of the company's stock, valued at approximately $610,000. Several other hedge funds and other
Qiagen N.V. (QGEN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Qiagen N.V. (QGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Why Is Qiagen (QGEN) Down 9.4% Since Last Earnings Report?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Qiagen N.V. (QGEN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Qiagen N.V. (QGEN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down
QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.
Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript
Qiagen N.V. (QGEN) Q4 2025 Earnings Call Transcript
Qiagen (QGEN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Meets Q4 Earnings Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.64 per share a year ago.
Earnings Preview: Qiagen (QGEN) Q4 Earnings Expected to Decline
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen: Takeover Optionality With A High-Quality Consumables Platform
QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there's renewed takeover speculation after reports that show they're weighing strategic options. QGEN's potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed.
